Clinical trial NCT02973399: Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Official title: A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cancer
Keywords: CLL
Leukemia, Chronic Lymphocytic
Hsp90
Ibrutinib
Lead sponsor: Esanex Inc.
Sponsor class: INDUSTRY
First posted: 2016-11-25
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in subjects who have residual disease, but have not progressed on ibrutinib after 18 months of monotherapy, and/or prevents or delays disease progression of subjects with CLL.

Detailed description: Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults and is not considered curable outside of allogeneic stem cell transplantation. Significant advances have been made in the therapy, notably with the introduction of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib.

While response to ibrutinib has been high with therapy well-tolerated overall, some patients have relapsed while others have been taken off therapy for toxicity or other reasons. In addition, although remissions are durable in many patients, very few patients achieve a complete response (CR), and minimal residual disease (MRD) negativity on single agent ibrutinib has not been reported. Since it is known that for chemoimmunotherapy as well as targeted therapies such as venetoclax that attainment of a CR is associated with longer progression free survival (PFS), it is likely that deepening responses associated with ibrutinib will result in more durable remissions.

Relapse in CLL can be mediated by at least two separate mechanisms. One is by mutations in BTK, the other is through a variety of mutations in the immediate downstream target of BTK, PLCγ2. SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in subjects who have residual disease, but have not progressed on ibrutinib after 18 months of monotherapy.

Subjects will receive SNX-5422 (56 mg/m2) in the morning once every other day for 21 days (11 doses), followed by a 7-day drug-free period. Subjects will continue to receive daily oral ibrutinib at their established dose level in the afternoon

Eligibility criteria: Inclusion Criteria:

* Males or non-pregnant, non-breastfeeding females 18 years-of-age or older
* A diagnosis of CLL as defined by IWCLL 2008 criteria and currently on treatment with ibrutinib for at least 18 months with residual disease and without evidence of disease progression.
* No more than 4 prior lines of anti leukemia therapy (not including ibrutinib)
* Life expectancy of at least 9 months
* Karnofsky performance score 70
* Adequate baseline laboratory assessments
* Signed informed consent form
* Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1
* Subjects with reproductive capability must agree to practice adequate contraception methods.

Exclusion Criteria:

* Subjects experiencing toxicity with ibrutinib
* Prior treatment with any Hsp90 inhibitor.
* Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
* Conventional chemotherapy or radiation within 4 weeks.
* The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422
* Screening ECG QTc interval 470 msec for females, 450 msec for males.
* At increased risk for developing prolonged QT interval unless corrected to within normal limits prior to first dose of SNX-5422
* Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
* Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety
* History of documented adrenal dysfunction not due to malignancy.
* History of chronic liver disease.
* Active hepatitis A or B.
* Current alcohol dependence or drug abuse.
* Use of an investigational treatment (except for ibrutinib) from 30 days prior to the first dose
* Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination that are considered clinically important by examiner.
* Psychological or social reasons that would hinder or prevent compliance with the requirements of the protocol or compromise the informed consent process.

Primary outcomes:
measure: Efficacy of the combination of SNX-5422 and ibrutinib
timeFrame: 6 months
Secondary outcomes:
measure: Number of subjects reporting adverse events
timeFrame: Day 28 of each 4 week cycle from randomization up to 52 weeks
measure: Complete response at 12 months
timeFrame: 12 months
measure: Improved Clinical Status
timeFrame: 6 months
measure: Progression free survival of patients receiving ibrutinib plus SNX-5422
timeFrame: Up to 52 weeks
Other outcomes:
measure: BTK Mutation Level
timeFrame: 6 and 12 months
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
city: Columbus
country: United States
facility: Wexner Medical Center, Ohio State University
state: Ohio
Study officials:
References: